Lifestyle WellnessGalderma Survey Shows Long-Lasting Results Drive Anti-Wrinkle Treatment Dec... Galderma Survey Shows Long-Lasting Results Drive Anti-Wrinkle Treatment Dec... Read Post »
Clinical TrialsVenetoclax Plus Obinutuzumab Cuts Risk of Progression or Death by 50% in CL... Venetoclax Plus Obinutuzumab Cuts Risk of Progression or Death by 50% in CL... Read Post »
Health TidingsGSK Secures Orphan Drug Designations in US and EU for Momelotinib in VEXAS ... GSK Secures Orphan Drug Designations in US and EU for Momelotinib in VEXAS ... Read Post »
Clinical TrialsGenmab’s Epcoritamab Plus R2 Maintains Strong Benefit Across Risk Gro... Genmab’s Epcoritamab Plus R2 Maintains Strong Benefit Across Risk Gro... Read Post »
Health TidingsCaliway’s CBL-514 Cuts Weight Regain When Added to Tirzepatide in Pre... Caliway’s CBL-514 Cuts Weight Regain When Added to Tirzepatide in Pre... Read Post »
Clinical TrialsCullinan Reports Promising Phase 1 Results for CLN-978 and Velinotamig Cullinan Reports Promising Phase 1 Results for CLN-978 and Velinotamig Read Post »
Clinical TrialsFDA Backs Phase 3 Plan as Enliven Posts Strong Phase 1 CML Results FDA Backs Phase 3 Plan as Enliven Posts Strong Phase 1 CML Results Read Post »
Health TidingsNovartis Reports Positive FORTITUDE Data for Del-Brax in FSHD Novartis Reports Positive FORTITUDE Data for Del-Brax in FSHD Read Post »
Health TidingsTakeda Reports Phase 3 Win for Zasocitinib in Plaque Psoriasis Takeda Reports Phase 3 Win for Zasocitinib in Plaque Psoriasis Read Post »
Health TidingsCASGEVY Extends Durable Clinical Benefit to Children With SCD and TDT CASGEVY Extends Durable Clinical Benefit to Children With SCD and TDT Read Post »
Health TidingsCemsidomide Achieves 53% Response Rate in Phase 1/2 Multiple Myeloma Trial Cemsidomide Achieves 53% Response Rate in Phase 1/2 Multiple Myeloma Trial Read Post »
Clinical TrialsZiftomenib + 7+3 Achieves 94% One-Year Survival in NPM1-Mutant AML in KOMET... Ziftomenib + 7+3 Achieves 94% One-Year Survival in NPM1-Mutant AML in KOMET... Read Post »
Clinical TrialsSix-Year SEQUOIA Data Highlight Durable BRUKINSA Benefit in CLL Patients Ag... Six-Year SEQUOIA Data Highlight Durable BRUKINSA Benefit in CLL Patients Ag... Read Post »
Clinical TrialsJohnson & Johnson Strengthens IMAAVY FDA Filing With Positive ENERGY Re... Johnson & Johnson Strengthens IMAAVY FDA Filing With Positive ENERGY Re... Read Post »
Health TidingsFDA Delays CAM2029 Approval in Acromegaly Over Manufacturing Issues FDA Delays CAM2029 Approval in Acromegaly Over Manufacturing Issues Read Post »
Health TidingsFDA Grants Priority Review to Roche’s Tecentriq in Early-Stage Colon Canc... FDA Grants Priority Review to Roche’s Tecentriq in Early-Stage Colon Canc... Read Post »
Health Tidings Mergers & AcquisitionsServier, n-Lorem Launch ASO Research Partnership in Rare Neurology Servier, n-Lorem Launch ASO Research Partnership in Rare Neurology Read Post »
Health Tidings Mergers & AcquisitionsNovartis Expands Orionis Partnership in $1.4 Billion Molecular Glue Drug Di... Novartis Expands Orionis Partnership in $1.4 Billion Molecular Glue Drug Di... Read Post »
Health TidingsOno Files VELEXBRU Expansion in Japan for Secondary CNS Lymphoma Ono Files VELEXBRU Expansion in Japan for Secondary CNS Lymphoma Read Post »
New Drug ApprovalFDA Expands Organon’s TOFIDENCE Biosimilar Approval to CAR-T CRS and COVI... FDA Expands Organon’s TOFIDENCE Biosimilar Approval to CAR-T CRS and COVI... Read Post »
Drugs Safety AlertFDA Updates Alli Label to Warn of Rare Risk of Acute Kidney Injury and Kidn... FDA Updates Alli Label to Warn of Rare Risk of Acute Kidney Injury and Kidn... Read Post »
Health TidingsWhat Zepbound and Shaquille O’Neal’s Story Reveal About Undiagn... What Zepbound and Shaquille O’Neal’s Story Reveal About Undiagn... Read Post »
Health TidingsEMA Begins Review of Bayer’s Asundexian for Secondary Stroke Prevention EMA Begins Review of Bayer’s Asundexian for Secondary Stroke Prevention Read Post »
Clinical TrialsSanofi Halts Phase 3 MOBILIZE Trial of Riliprubart in Refractory CIDP Sanofi Halts Phase 3 MOBILIZE Trial of Riliprubart in Refractory CIDP Read Post »
Health TidingsFDA Accepts Takeda’s ENTYVIO sBLA for Pediatric Ulcerative Colitis and Cr... FDA Accepts Takeda’s ENTYVIO sBLA for Pediatric Ulcerative Colitis and Cr... Read Post »
Health TidingsBausch Health Secures Key Reimbursement Milestone for PrOKEDI in Canada Bausch Health Secures Key Reimbursement Milestone for PrOKEDI in Canada Read Post »
Health Tidings Mergers & AcquisitionsLilly Signs Potential $1 Billion Alzheimer’s Deal With AlzeCure Lilly Signs Potential $1 Billion Alzheimer’s Deal With AlzeCure Read Post »
Clinical TrialsFDA Aligns on Phase 3 Design for Alterity’s ATH434 in MSA FDA Aligns on Phase 3 Design for Alterity’s ATH434 in MSA Read Post »
New Drug ApprovalFDA Approves Every-8-Week EBGLYSS Dosing for Atopic Dermatitis FDA Approves Every-8-Week EBGLYSS Dosing for Atopic Dermatitis Read Post »
New Drug ApprovalFDA Adds Bemotrizinol to OTC Sunscreen Monograph, First New UV Filter in Ov... FDA Adds Bemotrizinol to OTC Sunscreen Monograph, First New UV Filter in Ov... Read Post »
Health TidingsTeva Presents New AUSTEDO Data Across the Tardive Dyskinesia Care Continuum Teva Presents New AUSTEDO Data Across the Tardive Dyskinesia Care Continuum Read Post »
Health TidingsNMPA Approves TIVDAK for Recurrent or Metastatic Cervical Cancer NMPA Approves TIVDAK for Recurrent or Metastatic Cervical Cancer Read Post »
Clinical TrialsTango Sets Phase 3 Course for Vopimetostat-Daraxonrasib in MTAP-Deleted PDA... Tango Sets Phase 3 Course for Vopimetostat-Daraxonrasib in MTAP-Deleted PDA... Read Post »
New Drug ApprovalMHRA Grants Authorization for Nipocalimab in gMG MHRA Grants Authorization for Nipocalimab in gMG Read Post »
Clinical Trials82% of Patients Respond to BRIUMVI in Early Myasthenia Gravis Study 82% of Patients Respond to BRIUMVI in Early Myasthenia Gravis Study Read Post »
Clinical TrialsGilead and Merck’s Once-Weekly HIV Pill Meets Phase 3 Goals Gilead and Merck’s Once-Weekly HIV Pill Meets Phase 3 Goals Read Post »
Health Tidings Mergers & AcquisitionsGSK Acquires Nuvalent, Adding FDA-Reviewed ROS1 and ALK Inhibitors GSK Acquires Nuvalent, Adding FDA-Reviewed ROS1 and ALK Inhibitors Read Post »
Health TidingsMerck and Gilead Halt Phase 3 KEYNOTE-D46/EVOKE-03 Study Over Missing PFS E... Merck and Gilead Halt Phase 3 KEYNOTE-D46/EVOKE-03 Study Over Missing PFS E... Read Post »
Clinical TrialsLilly’s Oral GLP-1 Foundayo Shows Clear Edge Over Oral Semaglutide Lilly’s Oral GLP-1 Foundayo Shows Clear Edge Over Oral Semaglutide Read Post »
Mergers & AcquisitionsJohnson & Johnson Acquires Firefly Bio in $1 Billion Oncology Deal Johnson & Johnson Acquires Firefly Bio in $1 Billion Oncology Deal Read Post »
Health TidingsUK Clears Moderna’s mRNA-4194 for Lynch Syndrome Cancer Prevention Study UK Clears Moderna’s mRNA-4194 for Lynch Syndrome Cancer Prevention Study Read Post »
Clinical TrialsElecoglipron Lowers HbA1c by 1.9% and Drives Weight Loss in Phase 2b Studie... Elecoglipron Lowers HbA1c by 1.9% and Drives Weight Loss in Phase 2b Studie... Read Post »
Clinical TrialsSurvodutide Delivers Up to 16.6% Weight Loss and Reduces Liver Fat in Phase... Survodutide Delivers Up to 16.6% Weight Loss and Reduces Liver Fat in Phase... Read Post »
Health Tidings Mergers & AcquisitionsRoche Licenses Nurix’s BTK Degrader Bexobrutideg in Up to $2.3 Billion De... Roche Licenses Nurix’s BTK Degrader Bexobrutideg in Up to $2.3 Billion De... Read Post »
Health Tidings Mergers & AcquisitionsIncyte Bolsters Hematology Growth With $2 Billion Vega Buyout Incyte Bolsters Hematology Growth With $2 Billion Vega Buyout Read Post »
Health TidingsKorlym Cuts HbA1c and Weight in Difficult-to-Control Diabetes Linked to Hyp... Korlym Cuts HbA1c and Weight in Difficult-to-Control Diabetes Linked to Hyp... Read Post »
ResearchINGREZZA Delivered Rapid Tardive Dyskinesia Improvement in Patients With ID... INGREZZA Delivered Rapid Tardive Dyskinesia Improvement in Patients With ID... Read Post »
Clinical TrialsCullinan Therapeutics Delivers CLN-978 Remission in Lupus and RA Cullinan Therapeutics Delivers CLN-978 Remission in Lupus and RA Read Post »
Clinical TrialsCagriSema Delivers Superior HbA1c and Weight Reduction Across Phase 3 REIMA... CagriSema Delivers Superior HbA1c and Weight Reduction Across Phase 3 REIMA... Read Post »
Health TidingsFDA Review Accepted for Alvotech’s Vedolizumab Biosimilar FDA Review Accepted for Alvotech’s Vedolizumab Biosimilar Read Post »
